Ani Pharmaceuticals (ANIP) Free Cash Flow Growth (1y) (2011 - 2026)
Powered by 
Analysis
Ani Pharmaceuticals (ANIP) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 134.35% |
| 2 | Viatris | 19.20 Bn | 18.31 Bn | 1.46 Bn | 97.24% |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.73 Bn | 396.53 Mn | -89.49% |
| 4 | Amneal Pharmaceuticals | 5.49 Bn | 5.36 Bn | 334.51 Mn | -185.16% |
| 5 | Bausch Health Companies | 2.31 Bn | 475.75 Mn | 2.10 Bn | 212.11% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | - |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | -25.33% |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 711.29 Mn | 93.47 Mn | 70.75% |
| 9 | Fennec Pharmaceuticals | 396.40 Mn | 355.15 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -25.33% |
| Mar 31, 2026 | 60.84% |
| Dec 31, 2025 | 116.27% |
| Sep 30, 2025 | 395.33% |
| Jun 30, 2025 | 453.78% |
| Mar 31, 2025 | 137.56% |
| Dec 31, 2024 | -68.29% |
| Sep 30, 2024 | -74.82% |
| Jun 30, 2024 | -28.47% |
| Mar 31, 2024 | -28.24% |
| Dec 31, 2023 | 663.29% |
| Sep 30, 2023 | 2,534.63% |
| Jun 30, 2023 | 241.55% |
| Mar 31, 2023 | 191.31% |
| Dec 31, 2022 | 39.89% |
| Sep 30, 2022 | 119.34% |
| Jun 30, 2022 | -1,753.11% |
| Mar 31, 2022 | -204.61% |
| Dec 31, 2021 | -60.39% |
| Sep 30, 2021 | -76.98% |